BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-298@pharmaconomics
DTSTAMP:20260707T015553Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:HRMY Phase 1 — Orexin-2 receptor agonist (BP1.15205)
DESCRIPTION:Phase 1 trial results for Orexin-2 receptor agonist (BP1.15205) in its lead indication are due Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1802665/000110465926002731/hrmy-20260112xex99d1.htm\n\nTrack it: https://pharmaconomics.com/e/298
URL:https://pharmaconomics.com/e/298
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:HRMY catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR